Holoclar® (Ex vivo expanded autologous human corneal epithelial cells containing stem cells): A Comprehensive Analysis of a Pioneering Regenerative Therapy for Limbal Stem Cell Deficiency

The Pathophysiological Basis for Regenerative Intervention in Limbal Stem Cell Deficiency (LSCD)

The Limbal Niche and Corneal Homeostasis

The human cornea, a transparent and avascular tissue at the front of the eye, is essential for vision. Its integrity is maintained by a continuous process of cellular renewal orchestrated by a specialized population of unipotent adult stem cells known as limbal epithelial stem cells (LESCs), or corneal epithelial stem cells.[1] These cells reside in the basal epithelial layer of the limbus, a narrow transitional zone at the border between the cornea and the sclera.[3] This region, characterized by anatomical structures called the palisades of Vogt, forms a unique microenvironment or "niche" that protects LESCs from environmental insults and regulates their function.[6]

The primary physiological role of LESCs is to serve as the ultimate source for the lifelong regeneration of the corneal epithelium. These stem cells possess a high proliferative potential and a slow turnover rate, characteristics that allow them to persist throughout an individual's life.[1] In response to natural cell shedding or injury, LESCs divide to produce transient amplifying cells (TACs). These TACs undergo a series of rapid divisions and migrate centripetally from the limbus to the central cornea, progressively differentiating into mature, terminally differentiated corneal epithelial cells that form the superficial layers of the cornea before being shed into the tear film.[9] This hierarchical system of stem cells, progenitors, and differentiated cells is fundamental to maintaining a smooth, transparent, and stable corneal surface, which is a prerequisite for clear vision.[9]

Etiology and Clinical Manifestations of LSCD

Limbal Stem Cell Deficiency (LSCD) is a severe ocular surface disease defined by the functional failure or depletion of the LESC population.[11] While LSCD can arise from various congenital or acquired causes, the indication for Holoclar® specifically targets one of the most devastating etiologies: severe physical or chemical ocular burns.[14] These traumatic injuries, often occurring in industrial or domestic settings from exposure to alkalis, acids, or extreme heat, can catastrophically destroy the limbal niche and its resident stem cell population.[4]

The loss of a functional LESC pool triggers a cascade of debilitating pathological changes. The limbal barrier, which normally prevents conjunctival tissue from encroaching onto the cornea, breaks down. This leads to a process known as "conjunctivalization," where the transparent corneal epithelium is replaced by opaque, vascularized conjunctival epithelium.[9] Clinically, this manifests as superficial corneal neovascularization (the ingrowth of new blood vessels), chronic inflammation, persistent epithelial defects, stromal scarring, and progressive corneal opacification.[5]

For the patient, the consequences are profound and life-altering. The condition is characterized by chronic and severe symptoms, including intense pain, a persistent burning sensation, and debilitating photophobia (light sensitivity).[16] Ultimately, the loss of corneal transparency leads to severely impaired visual acuity or complete blindness, profoundly impacting the patient's quality of life, ability to work, and social functioning.[23]

The Unmet Need and Rationale for Stem Cell Therapy

In the context of severe LSCD, conventional corneal transplantation (keratoplasty) is destined to fail. A standard donor cornea graft, while replacing the opaque stromal tissue, does not address the underlying pathology—the absence of a host stem cell population. Without functional LESCs to continuously renew its surface, the donor cornea becomes conjunctivalized and opacifies, leading to graft failure.[6] This highlights a critical unmet medical need for a therapy that can restore the fundamental regenerative capacity of the eye.

Prior to the development of Holoclar®, surgical options were limited and fraught with significant drawbacks. Conjunctival Limbal Autograft (CLAU), which involves transplanting a large section of limbal tissue from the patient's healthy eye, carries a substantial risk of inducing iatrogenic LSCD in the donor eye.[23] Allogeneic transplantation, using tissue from a living relative or a cadaveric donor (Kerato-limbal allograft or KLAL), necessitates long-term systemic immunosuppression to prevent graft rejection, exposing the patient to the risks of infection and systemic toxicity.[1]

This therapeutic gap created a clear and compelling rationale for the development of a regenerative medicine approach. The central hypothesis was that by harvesting a small, safe amount of tissue from a patient's healthy limbus, expanding the LESC population ex vivo in a controlled laboratory setting, and transplanting the resulting cellular sheet back to the damaged eye, it would be possible to permanently restore the stem cell pool and re-establish normal corneal homeostasis.[11] This approach, embodied by Holoclar®, promised to overcome the primary limitations of existing treatments by minimizing risk to the donor eye and avoiding the need for immunosuppression.

The strategic decision to focus the indication for this first-in-class therapy on burn-related LSCD was pivotal. This choice effectively isolated a structural deficit (a depleted stem cell pool from an acute, non-recurring injury) from more complex pathologies involving chronic, ongoing inflammation, such as autoimmune-driven LSCD. By targeting a condition where the primary failure is a lack of regenerative "hardware," the developers could design a clinical program where the success of the stem cell graft itself was the principal variable. This avoided the confounding challenge of managing a persistent underlying disease state, a critical simplification that likely contributed significantly to the ability to demonstrate efficacy and navigate the novel regulatory pathway for an advanced therapy medicinal product (ATMP).

Holoclar® - Product Composition and Mechanism of Action

A Living Tissue Equivalent

Holoclar® is classified as an advanced therapy medicinal product, specifically a "tissue engineered product," with its pharmaceutical form described as a "living tissue equivalent".[14] It is a transparent, circular sheet of viable, autologous human corneal epithelial cells designed for surgical implantation.[14]

The quantitative composition of the product is precisely defined. Each sheet contains a total of 300,000 to 1,200,000 viable cells, corresponding to a density of 79,000 to 316,000 cells per square centimeter (cells/cm2).[14] This cellular construct is not homogenous; it is a stratified epithelium composed of a mixed population of cells at different stages of the corneal epithelial hierarchy. This includes terminally differentiated cells, transient amplifying cells, and, most critically, a sub-population of limbal stem cells.[14] On average, these LESCs constitute 3.5% of the total cell population, with a specified range of 0.4% to 16%.[14]

This stem cell component is the biological engine of the therapy. These LESCs are characterized by their ability to form "holoclones," which are colonies derived from a single stem cell that exhibit the greatest long-term proliferative potential.[10] The presence of a sufficient percentage of these holoclone-forming cells, identified by the molecular marker p63, is a critical quality attribute that directly correlates with long-term clinical success.[13] To facilitate surgical handling and transplantation, this living cellular layer is attached to a supportive, biodegradable scaffold made of fibrin, a biological protein.[15]

Fundamentally, Holoclar® is not merely a suspension of cells but a functional, bioengineered organoid transplant. The manufacturing process is therefore not a simple exercise in cell expansion but a sophisticated bioengineering challenge focused on preserving the "stemness" and regenerative potential of the holoclone population. This transforms the concept of product quality from merely ensuring sterility and viability to guaranteeing biological potency. This complexity explains why not every patient biopsy can be successfully manufactured into a deliverable treatment; a failure to meet the release criteria, particularly regarding the stem cell content, represents a failure to produce a therapeutically effective product.[27]

Regenerative Mechanism

The mechanism of action of Holoclar® is the definitive biological reconstruction of the ocular surface through the replacement of the damaged corneal epithelium and, crucially, the permanent replenishment of the depleted limbal stem cell reservoir.[14]

Following surgical implantation onto the prepared corneal bed, the therapy exerts a dual-phase regenerative effect.

1. Immediate Surface Restoration: The numerous transient amplifying and terminally differentiated cells within the graft provide immediate coverage of the corneal surface, establishing a transient epithelial barrier.
2. Long-Term Regeneration: The transplanted limbal stem cells engraft into the patient's limbal niche. From this restored reservoir, these stem cells begin their physiological function of self-renewal and differentiation, providing a continuous, lifelong source of new epithelial cells to maintain the cornea.[2]

A core advantage of this therapy is its autologous nature. Because the cells are harvested from the patient, they are not recognized as foreign by the immune system. This completely obviates the risk of immune-mediated graft rejection and, consequently, eliminates the need for long-term systemic immunosuppressive therapy and its associated risks of toxicity and infection.[4]

The Clinical Development and Efficacy Profile of Holoclar®

Foundational Retrospective Evidence (Pre-2015)

The initial marketing authorisation for Holoclar® was granted on a conditional basis, supported by a body of evidence primarily derived from retrospective, uncontrolled case series studies.[15] This approach was deemed appropriate by regulators given the rarity of the condition and the significant unmet medical need.

The pivotal evidence came from the HLSTM01 study, which analyzed the past medical records of patients treated with the therapy. The primary efficacy outcome was defined as transplant success at 12 months post-implantation. Success was a composite endpoint requiring both a stable corneal epithelium (i.e., absence of epithelial defects) and the absence of significant recurrence of neovascularisation (defined as involvement of no more than one quadrant without central corneal involvement).[23] The headline result from this analysis was a transplant success rate of 72.1%, achieved in 75 of the 104 patients evaluated.[15]

Secondary efficacy assessments provided further support for the clinical benefit of the treatment. There were clinically meaningful reductions in ocular symptoms, with the proportion of patients reporting pain, burning, or photophobia decreasing significantly at 12 months.[15] Furthermore, visual acuity improved by at least one line on the Snellen chart in 49% of patients.[29] The therapy was also shown to be an effective preparatory step for subsequent corneal transplantation, with 42% of patients who underwent a post-Holoclar® keratoplasty having a successful outcome.[29] While this evidence was compelling, its retrospective and uncontrolled nature meant that further prospective data were required, leading the European Medicines Agency (EMA) to grant a conditional approval, contingent on the completion of a confirmatory trial.[3]

The HOLOCORE Prospective Confirmatory Trial (Post-2015)

As a condition of the marketing authorisation, the multinational, prospective, open-label HOLOCORE trial (EudraCT: 2014-002845-23) was initiated to confirm the safety and efficacy of Holoclar® in a controlled setting.[33] The study enrolled 80 patients with moderate to severe LSCD due to ocular burns, including 76 adults and 4 paediatric patients.[33]

The efficacy results from HOLOCORE presented a more nuanced picture than the earlier retrospective data. One summary of the trial reported a success rate of 41.0% in the adult population at one year (25 out of 61 evaluable patients).[33] Another report from the manufacturer clarified that success rates varied depending on the assessment criteria, ranging from a minimum of 51% when measured according to standardized Global Consensus guidelines, up to 77% based on ophthalmologist assessments.[37] This evolution in efficacy rates from the initial 72% in retrospective data to the 41-77% range in the prospective trial likely reflects the application of more stringent and standardized endpoint definitions in a formal clinical trial setting. Even with the lower-end success rate of approximately 50%, regulators evidently considered this level of benefit to be highly clinically meaningful for a severe orphan condition with no other approved treatments, setting an important precedent for the acceptable benefit-risk profile for a pioneering ATMP.

The trial confirmed the positive impact on patient symptoms, with 75.4% of patients reporting no burning sensation and 78.7% reporting no pain one year after the procedure.[33] A critical and unexpected finding from the HOLOCORE trial was that repeat implantations in patients whose first graft failed did not result in successful transplantation.[33] This finding has profound clinical implications, suggesting that the success of the therapy is highly dependent on the initial attempt and the receptiveness of the ocular surface environment. An initial failure may indicate a wound bed that is too inflamed, scarred, or otherwise hostile to support stem cell engraftment, meaning a second graft is likely to meet the same fate. This underscores the paramount importance of rigorous patient selection and pre-operative optimization of the ocular surface to maximize the chance of success on the first and potentially only attempt.

The successful completion and positive assessment of the HOLOCORE study provided the necessary confirmatory evidence for regulators. In February and March of 2024, the marketing authorisation for Holoclar® was converted from "conditional" to "full" or "standard" by the European Commission and the UK's MHRA, respectively, marking the culmination of its clinical development program.[37]

Long-Term Efficacy and Durability

The foundational research that led to Holoclar® demonstrated that the clinical benefits could be durable, with initial reports showing stable results for up to two years and subsequent follow-up extending to over 14 years in some cases.[23] To formally assess the long-term durability of the therapy in a broader population, two key studies are ongoing. The HOLOCORE-FU (Follow-Up) study (EudraCT: 2015-001344-11) is tracking patients from the main HOLOCORE trial to gather long-term safety and efficacy data.[33] Additionally, a post-authorisation safety study (PASS) named HOLOSIGHT is observing 100 patients treated in a real-world commercial setting for up to five years post-implantation to monitor long-term outcomes.[37] These studies will provide crucial data on the persistence of the regenerative effect and the long-term safety profile of this pioneering therapy.

Table 1: Summary of Key Clinical Trials for Holoclar®

Study Name	Study Design	Patient Population (N)	Primary Endpoint	Key Efficacy Results
HLSTM01	Retrospective Case Series	104	Transplant success at 12 months (stable epithelium without significant neovascularisation)	- 72.1% of patients achieved transplant success. - 49% of patients had improved visual acuity by ≥1 Snellen line.
HOLOCORE	Prospective, Open-Label, Uncontrolled	80 (76 adults, 4 paediatric)	Transplant success at 12 months	- Success rate of 41% to 77% in adults, depending on assessment criteria. - 78.7% of patients reported no pain at 12 months. - Repeat transplants after initial failure were not successful.

The Holoclar® Therapeutic Process: From Biopsy to Post-Operative Management

Patient Selection and Pre-Operative Assessment

The success of Holoclar® treatment is critically dependent on meticulous patient selection and a comprehensive pre-operative assessment. The therapeutic process is restricted to a highly specific patient population and requires a stable ocular environment to support graft engraftment.

Inclusion Criteria:

• Patient Population: The therapy is indicated for adult patients.[14]
• Diagnosis: Patients must have moderate to severe LSCD, which is clinically defined by the presence of superficial corneal neovascularisation in at least two corneal quadrants, with involvement of the central cornea, and severely impaired visual acuity.[14]
• Etiology: The LSCD must be a direct result of physical or chemical ocular burns.[14]
• Biopsy Requirement: A crucial and non-negotiable criterion is the presence of a minimum 1-2 mm2 area of undamaged limbus in at least one eye, from which a viable biopsy can be harvested.[14]

Exclusion Criteria and Management of Complicating Factors:

A thorough ophthalmological evaluation is mandatory to identify and address any conditions that could compromise the success of the implantation.17 Treatment must be deferred in patients with active, acute ocular inflammation or infections until the condition has resolved.27 Several co-existing ocular pathologies are considered significant complicating factors and must be surgically corrected

prior to the Holoclar® procedure. These include:

• Eyelid malposition (e.g., entropion, ectropion)
• Severe dry eye syndrome
• Conjunctival scarring with fornix shortening (symblepharon)
• Pterygium
• Corneal or conjunctival anaesthesia [17]

Finally, patients with a known history of hypersensitivity to murine (mouse) products or fetal bovine serum are contraindicated due to the use of these materials in the manufacturing process.[27]

Manufacturing and Surgical Administration

The Holoclar® therapeutic process is a complex, multi-step logistical chain that transforms it from a simple "product" into an integrated "product-as-a-service." This model, common to autologous cell therapies, involves two separate surgical procedures, time-sensitive and temperature-controlled transport, and a centralized, multi-week manufacturing cycle. This intricate process restricts treatment to a limited number of highly qualified and certified centers and underscores that the success of the therapy is as dependent on flawless logistical execution as it is on the underlying cell biology.[17]

Step 1: Biopsy Procurement

The process begins at the certified hospital with the first surgical procedure. A small biopsy, approximately 1-2 mm2, is harvested from an undamaged area of the patient's limbus under topical anaesthesia. The procedure involves a careful ocular surface lavage and detachment of the conjunctiva to expose the biopsy site.14 The harvested tissue is immediately placed into a sterile, validated transport medium provided by the manufacturer. This container must be shipped under controlled conditions and received by the manufacturing facility, Holostem Terapie Avanzate in Modena, Italy, within 24 hours of procurement to ensure cell viability.14

Step 2: GMP Manufacturing

Upon receipt at the Good Manufacturing Practice (GMP)-certified facility, the cells are isolated from the biopsy tissue. They are then cultured and expanded ex vivo. This primary culture is grown on a feeder layer of lethally-irradiated murine 3T3 fibroblast cells, which provide essential growth factors that promote the proliferation of LESCs while maintaining their "stemness." After sufficient expansion, the cells are harvested and cryopreserved, creating a master cell bank for the patient. When the patient is scheduled for surgery, a vial of these cells is thawed and seeded onto a supportive fibrin matrix for a secondary culture phase. This allows the cells to form a stratified epithelial sheet, which constitutes the final Holoclar® product. This entire manufacturing process takes several weeks to complete.15

Step 3: Surgical Implantation

The final living tissue equivalent, which resembles a soft contact lens, is packaged in a sterile container with transport medium and shipped back to the hospital for immediate implantation.4 The second surgical procedure begins with the surgeon preparing the recipient eye. This involves a limbal peritomy (an incision around the limbus) and the meticulous excision of the fibrovascular scar tissue (pannus) from the corneal surface. The Holoclar® sheet is then carefully placed onto the denuded cornea, trimmed to fit, and its edges are tucked under the undermined conjunctiva. The conjunctiva is then secured over the edge of the graft with two or three fine sutures (e.g., vicryl or silk 8/0) to protect the implant and ensure it remains in place.14 The entire implantation is typically performed under local anaesthesia, such as a retrobulbar or parabulbar block.14

Post-Implantation Care and Monitoring

A rigorous and specific post-operative management protocol is essential for the survival and successful engraftment of the Holoclar® graft. Immediately following surgery, the patient's eyelid is taped shut with a steri-strip for approximately three days, and the eye is covered with a protective bandage for 10 to 15 days to shield the delicate graft during the initial healing phase.[14]

A mandatory pharmacological regimen is initiated to prevent infection and control inflammation, which could otherwise lead to graft failure. This includes a course of prophylactic antibiotics and a carefully tapered course of topical corticosteroids. A typical corticosteroid regimen involves preservative-free dexamethasone 0.1% eye drops, starting two weeks post-surgery and gradually reducing the frequency over several weeks.[14]

Specific precautions are critical. Patients and healthcare providers must strictly avoid the use of any eye drops containing the preservative benzalkonium chloride or other quaternary ammonium compounds. These substances are cytotoxic and can severely damage the newly regenerating corneal epithelium, particularly the proliferative basal cells of the graft.[14] Additionally, the use of topical lidocaine or any anaesthetics containing adrenaline must be avoided during any step of the treatment or follow-up, as they can also be detrimental to the graft.[14] Patients are then followed closely to monitor for graft stability, epithelial healing, and any potential complications.

Comprehensive Safety and Tolerability Profile

Analysis of Adverse Events

The safety profile of Holoclar® has been established through clinical trials and post-marketing experience. The data indicate that while adverse reactions are common, they are predominantly ocular in nature and generally considered manageable.[15] It is important to distinguish between adverse events that are direct consequences of the two surgical procedures (biopsy and implantation) and those potentially related to the biological activity or failure of the Holoclar® product itself.

The safety profile of this therapy reveals a critical relationship between its efficacy and safety. The most severe adverse events, such as corneal perforation and ulcerative keratitis, are not independent toxicities but are direct consequences of the therapy's failure to achieve its primary endpoint of stable engraftment.[27] This intertwining of safety and efficacy is a defining characteristic of many regenerative therapies, meaning that any factor that diminishes the likelihood of success is also, by definition, a factor that increases safety risk. This has significant implications for patient counseling, informed consent, and post-operative monitoring.

Very Common Adverse Reaction (≥1/10):

• Blepharitis: Inflammation of the eyelid is the most frequently reported adverse reaction.[15]

Common Adverse Reactions (≥1/100 to <1/10):

• Eye Disorders: This category includes the most common events, many of which are related to the surgical trauma and healing process. They include eye pain, conjunctival haemorrhage, eye haemorrhage, corneal epithelium defect, glaucoma or increased intraocular pressure (often related to post-operative steroid use), and keratitis/ulcerative keratitis.[44]
• Procedural Complications: General eye operation complications are also classified as common.[44]

Uncommon Adverse Reactions (≥1/1,000 to <1/100):

• A wide range of less frequent ocular events have been reported, including corneal perforation, corneal thinning, photophobia, conjunctival adhesion, and corneal oedema.[44]
• Systemic events such as syncope vasovagal (fainting, often related to pain or anxiety around the procedure) and headache have also been observed.[44]
• Events related to graft failure, such as engraft failure and persistent corneal epithelial defect, are also classified as uncommon.[44]

Serious Adverse Reactions:

The most clinically significant risks associated with Holoclar® are severe ocular complications that can threaten the integrity of the eye. Corneal perforation and ulcerative keratitis are the most serious adverse reactions. These events typically occur within the first three months following implantation and are directly linked to poor corneal stem cell engraftment and the resulting instability of the corneal epithelium.27

Risk Management and Mitigation

Beyond the documented adverse events, a comprehensive risk management plan (RMP) is in place to address specific potential risks inherent to this type of biological therapy.[15]

• Hypersensitivity Risk: The manufacturing process for Holoclar® utilizes animal-derived materials, including lethally-irradiated murine (mouse) 3T3 fibroblast feeder cells and fetal bovine serum.[27] Although these are removed or present only in trace amounts in the final product, there is a risk of hypersensitivity reactions. Consequently, the treatment is strictly contraindicated in patients with a known allergy to these components.[27]
• Infectious Agent Transmission: As with any therapy derived from human tissue, there is a theoretical risk of transmitting infectious agents. This risk is considered low and is rigorously controlled through mandatory infectious disease screening of the patient prior to biopsy and comprehensive testing of the cell cultures for sterility and mycoplasma during the manufacturing process.[27]
• Educational Measures: A key component of the RMP is the provision of detailed educational materials for both healthcare professionals and patients.[14] These materials are designed to ensure the safe and effective use of Holoclar® by providing training on critical aspects of the therapeutic process, including:
• Strict patient selection criteria.
• Traceability procedures to ensure the autologous product is given to the correct patient.
• Detailed protocols for the biopsy, implantation, and post-operative care.
• Reinforcement of contraindications, especially the avoidance of eye drops containing benzalkonium chloride.
• Guidance on managing potential complications like glaucoma and blepharitis.
• Procedures for reporting suspected adverse reactions to regulatory authorities.[14]

Table 2: Tabulated Summary of Adverse Reactions with Holoclar®

(Based on MedDRA System Organ Class)

MedDRA System Organ Class	Adverse Reaction	Frequency
Infections and infestations	Corneal infection, conjunctivitis	Uncommon
Nervous system disorders	Syncope vasovagal, headache	Uncommon
Eye disorders	Blepharitis	Very Common
	Conjunctival haemorrhage, eye haemorrhage, corneal epithelium defect, corneal abrasion/erosion, glaucoma/intraocular pressure increased, keratitis/ulcerative keratitis, eye pain	Common
	Conjunctival adhesion, conjunctival granuloma, conjunctival hyperaemia, corneal...source	Eye operation complication
	Engraft failure, suture rupture, persistent corneal epithelial defect, procedural vomiting	Uncommon

Regulatory and Commercial Landscape

A Landmark Approval in Europe

The regulatory journey of Holoclar® represents a seminal chapter in the history of regenerative medicine. It was the first therapy containing stem cells to successfully navigate the rigorous European Union regulatory framework, culminating in a centralized marketing authorisation.[3] This achievement established a viable pathway for future ATMPs and provided a crucial proof-of-concept for the entire field.

The key milestones in this pioneering journey include:

• Orphan Drug Designation (November 2008): Recognizing the rarity of LSCD due to burns, the EMA granted Holoclar® orphan medicine status, which provides incentives for the development of treatments for rare diseases.[15]
• Specialized Assessment: As an ATMP, the marketing authorisation application was assessed by the EMA's expert Committee for Advanced Therapies (CAT) in conjunction with the Committee for Medicinal Products for Human Use (CHMP).[3]
• Conditional Marketing Authorisation (February 2015): Based on promising but incomplete retrospective data, the EMA utilized its adaptive pathway mechanism to grant a conditional approval. This allowed early patient access to a breakthrough therapy for a condition with high unmet need, while requiring the company to provide more comprehensive prospective data to confirm the benefit-risk balance.[3]
• Full Marketing Authorisation (February 2024): Following the successful completion and positive review of the prospective HOLOCORE clinical trial, the European Commission converted the conditional approval to a full, standard marketing authorisation, validating the therapy's long-term safety and efficacy profile.[37]

Global Regulatory Status: A Tale of Two Continents

The regulatory success of Holoclar® in Europe stands in contrast to its status in the United States. In April 2018, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to GPLSCD01, the investigational product equivalent to Holoclar®, for the treatment of LSCD.[20] This designation provides development incentives but is distinct from marketing approval. To date, the therapy is not approved for commercial use in the U.S..[20] This divergence may reflect different regulatory philosophies and historical precedents; indeed, early attempts to introduce similar cell-based corneal therapies in the U.S. were halted due to regulatory requirements, suggesting a more challenging pathway for such products in that jurisdiction.[40]

The Development Engine: Holostem, De Luca, and Pellegrini

The story of Holoclar® is a powerful case study in the successful translation of academic discovery into a commercial therapeutic, bridging the notorious "valley of death" in biotechnology. The therapy is the culmination of more than two decades of foundational research in epithelial stem cell biology led by Professors Michele De Luca and Graziella Pellegrini at the University of Modena and Reggio Emilia in Italy.[4] Their group was instrumental in identifying and learning how to culture LESCs and in discovering the transcription factor p63 as a key molecular marker for these stem cells, a finding that became essential for defining the potency of the final product.[28]

While the scientific brilliance was the foundation, it was not sufficient to bring the therapy to patients. The introduction of new, stringent EU regulations for ATMPs in 2007, which treated cell therapies as medicines, necessitated an industrial approach to manufacturing and clinical development.[28] This regulatory shift was the catalyst for the creation of Holostem Terapie Avanzate in 2008.[16]

Holostem was established as a university spin-off through a strategic, tripartite public-private partnership. This model combined the pioneering science of De Luca and Pellegrini, the institutional support of the University of Modena and Reggio Emilia, and the crucial industrial and financial backing of Chiesi Farmaceutici, a major Italian pharmaceutical company.[34] Chiesi provided the investment, regulatory expertise, and pharmaceutical know-how required to build a GMP-certified manufacturing facility, conduct formal clinical trials, and navigate the complex marketing authorisation process. This collaborative model proved to be the essential vehicle for translating a complex, capital-intensive ATMP from the laboratory to the clinic and serves as a powerful blueprint for academic-to-industrial translation in the field of regenerative medicine.

Comparative Therapeutic Analysis and Future Perspectives

Holoclar® vs. Alternative Surgical Interventions

Holoclar® occupies a distinct and strategic niche within the treatment algorithm for severe LSCD, offering significant advantages over pre-existing surgical interventions. Its value proposition is best understood through a comparative analysis.

• vs. Autologous Grafts (CLAU and SLET): Compared to the traditional Conjunctival Limbal Autograft (CLAU) procedure, Holoclar's most significant advantage is the minimally invasive nature of its biopsy. Requiring only a 1-2 mm2 piece of tissue, it dramatically reduces the amount of tissue harvested from the patient's healthy donor eye compared to the several clock hours required for CLAU, thereby minimizing the risk of causing iatrogenic LSCD in the patient's only good eye.[23] Simple Limbal Epithelial Transplantation (SLET) also utilizes a small biopsy but relies on the transplanted tissue fragments to expand in vivo on the ocular surface. In contrast, Holoclar® employs a controlled ex vivo expansion process, which allows for rigorous quality control, confirmation of stem cell content, and the potential for cryopreservation of cells for future use.[24]
• vs. Allografts (KLAL): As an autologous therapy, Holoclar® fundamentally circumvents the primary challenge of allogeneic transplantation (using tissue from a cadaveric or living-related donor). It eliminates the risk of immune-mediated graft rejection. This, in turn, obviates the need for long-term systemic immunosuppression, sparing the patient from the significant side effects and risks associated with these medications, such as infection, renal toxicity, and metabolic disturbances.[1]
• vs. Boston Keratoprosthesis (KPro): The Boston KPro is not a direct competitor to Holoclar® but rather a treatment for a different stage or type of ocular surface failure. Holoclar® is a biological, regenerative therapy designed to restore the eye's natural physiology in patients who still have a viable ocular surface environment. The KPro, by contrast, is an artificial, prosthetic device. It is a salvage procedure for end-stage eyes where biological reconstruction has already failed or is contraindicated due to conditions like severe keratinization, profound dry eye, or bilateral blindness with no available autologous tissue source.[22] Ocular surface transplantation with a therapy like Holoclar® is often considered the primary procedure, with the KPro reserved as a last resort.[64]

Table 3: Comparative Analysis of Treatments for Severe LSCD

Treatment	Mechanism	Donor Source	Biopsy Size	Immunosuppression	Reported Success Rate	Key Advantages / Disadvantages
Holoclar®	Regenerative	Autologous	1-2 mm2	No	41% - 77%	Adv: Minimal risk to donor eye; no immunosuppression; GMP quality control. Disadv: Complex logistics; manufacturing failure possible; not for bilateral disease.
CLAU	Regenerative	Autologous	2-4 clock hours	No	~50%	Adv: Single surgical procedure; no immunosuppression. Disadv: Significant risk of damage to healthy donor eye.
SLET	Regenerative	Autologous	~1 clock hour	No	Variable	Adv: Minimal risk to donor eye; single-day procedure. Disadv: Relies on in vivo expansion; less controlled.
KLAL	Regenerative	Allogeneic	Full thickness graft	Yes	Variable, ~60%	Adv: Option for bilateral disease. Disadv: Requires lifelong immunosuppression; risk of rejection and graft failure.
Boston KPro	Prosthetic	Artificial	N/A	No	Variable	Adv: Option for end-stage disease/failed grafts. Disadv: High risk of complications (glaucoma, infection, melt); not a biological solution.

The Impact of Holoclar® on Regenerative Medicine

The approval and successful commercialisation of Holoclar® was a watershed moment for the entire field of regenerative medicine.[10] Its journey from academic research to an approved pharmaceutical product provided the first definitive proof-of-concept that a complex, living, stem cell-based therapy could successfully meet the stringent quality, safety, and efficacy standards required by modern drug regulatory agencies.[10]

This achievement had several profound impacts. First, it de-risked the field for other developers, investors, and pharmaceutical companies by demonstrating that a viable regulatory and commercial path exists for ATMPs. Second, it established a tangible roadmap, providing invaluable lessons in navigating the unique challenges of ATMP development, including GMP manufacturing of living tissues, complex logistics for autologous therapies, and the design of clinical trials for regenerative endpoints.[10] By proving it could be done, Holoclar® helped legitimize stem cell therapy as a real therapeutic modality, moving it from the realm of speculative science to clinical reality.

The Next Frontier in Corneal Regeneration

The legacy of Holoclar® is not only the treatment itself but also the roadmap it has created for future innovation. The specific limitations and challenges associated with Holoclar® have become the primary research and development objectives for the next generation of corneal regenerative therapies, catalyzing a wave of targeted innovation.

• Next-Generation CLET: The reliance of Holoclar® on animal-derived manufacturing components (murine feeder cells, bovine serum) has spurred the development of xenobiotic-free and serum-free culture systems. Therapies like Cultivated Autologous Limbal Epithelial Cells (CALEC), currently in clinical trials in the U.S., represent a direct evolution of the Holoclar® concept, aiming to improve the safety and consistency of the manufacturing process.[39]
• Alternative Cell Sources for Bilateral Disease: The major limitation of Holoclar® is its requirement for a healthy donor eye, making it unsuitable for patients with severe bilateral LSCD. This has driven research into alternative autologous cell sources. The most advanced of these is Cultivated Oral Mucosal Epithelial Transplantation (COMET), where epithelial cells from a small biopsy of the patient's mouth are expanded and transplanted to the ocular surface. This approach is already approved in Japan and is a promising option for patients with no remaining limbal tissue.[13]
• Emerging Therapeutic Paradigms: Looking further ahead, the field is exploring approaches that move beyond direct epithelial cell replacement. These include:
• Mesenchymal Stem Cells (MSCs): These cells, often derived from bone marrow or adipose tissue, are being investigated not for their ability to form cornea, but for their powerful immunomodulatory and anti-scarring properties, which could help create a more favorable environment for regeneration.[8]
• Cell-Free Therapies: A particularly exciting frontier is the use of cell-free products, such as exosomes. These are nanoscale vesicles secreted by stem cells that contain a cargo of proteins and RNA. The hypothesis is that these exosomes can be administered topically to deliver the regenerative signals of stem cells without the complexity, cost, and risk of transplanting living cells.[73]
• Advanced Bioengineering: Ultimately, the field aims to bioengineer entire corneal tissues. Research into novel hydrogel scaffolds, acellular corneal matrices, and 3D bioprinting seeks to create off-the-shelf solutions that could eliminate the need for donor tissue entirely, addressing the global shortage of donor corneas.[73]

Conclusions

Ex vivo expanded autologous human corneal epithelial cells containing stem cells, marketed as Holoclar®, represents a landmark achievement in medicine. As the first stem cell-based therapy to receive marketing authorisation in the Western world, it has successfully translated decades of pioneering academic research into a viable clinical treatment for patients suffering from moderate to severe Limbal Stem Cell Deficiency due to ocular burns.

The therapy's mechanism, which involves the transplantation of a bioengineered, living tissue equivalent to replenish the patient's own depleted stem cell pool, offers a truly regenerative solution for a debilitating condition that was previously untreatable by conventional means. Clinical data, from initial retrospective studies to the prospective HOLOCORE trial, have confirmed its ability to restore a stable corneal surface, alleviate severe symptoms, and improve vision in a significant proportion of patients, leading to its full marketing authorisation in Europe.

However, the analysis of Holoclar® also highlights the profound challenges inherent in this new class of medicines. Its complex "product-as-a-service" model, which intertwines surgery, logistics, and centralized manufacturing, presents significant hurdles to widespread patient access and scalability. Furthermore, the clinical evidence underscores the critical importance of patient selection and the receptiveness of the ocular surface environment, with the therapy's success appearing to be a "one-shot" opportunity where initial failure is not easily remedied by retreatment.

Ultimately, the legacy of Holoclar® extends far beyond its own clinical application. It has forged a regulatory and manufacturing pathway for future ATMPs, de-risking the field and providing an invaluable blueprint for translating advanced therapies from the laboratory to the clinic. Its successes and limitations have defined the key research and development objectives for the next wave of innovation in corneal regeneration, catalyzing the pursuit of xenobiotic-free manufacturing, alternative cell sources for bilateral disease, and novel cell-free and bioengineering approaches. Holoclar® is not merely a treatment; it is a foundational pillar upon which the future of regenerative ophthalmology is being built.

Works cited

1. Limbal stem cell - Wikipedia, accessed September 9, 2025, https://en.wikipedia.org/wiki/Limbal_stem_cell
2. Stem cell-based therapy | Holostem S.r.l., accessed September 9, 2025, https://www.holostem.com/therapies/stem-cell-based-therapy-for-corneal-surface-regeneration/?lang=en
3. Europe gains access to first stem cell drug - PMLiVE, accessed September 9, 2025, https://pmlive.com/pharma_news/europe_gains_access_to_first_stem_cell_drug_656927/
4. Europe approves Holoclar®, the first stem cell-based medicinal product | Eurostemcell, accessed September 9, 2025, https://www.eurostemcell.org/story/europe-approves-holoclar-first-stem-cell-based-medicinal-product
5. Diagnostic approach to limbal stem cell deficiency - Frontiers, accessed September 9, 2025, https://www.frontiersin.org/journals/ophthalmology/articles/10.3389/fopht.2024.1524595/full
6. Derivation of Limbal Stem Cells from Human Adult Mesenchymal Stem Cells for the Treatment of Limbal Stem Cell Deficiency - MDPI, accessed September 9, 2025, https://www.mdpi.com/1422-0067/24/3/2350
7. Therapeutic Strategies for Restoring Perturbed Corneal Epithelial Homeostasis in Limbal Stem Cell Deficiency: Current Trends and Future Directions - MDPI, accessed September 9, 2025, https://www.mdpi.com/2073-4409/11/20/3247
8. An updated narrative review of treatment for limbal epithelial stem cell deficiency - Park, accessed September 9, 2025, https://aes.amegroups.org/article/view/7404/html
9. Limbal Stem Cell Transplantation: Clinical Results, Limits, and ..., accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6201383/
10. Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union - PMC, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5746151/
11. Ex vivo expanded autologous limbal epithelial cells on amniotic membrane using a culture medium with human serum - OUS-research.no, accessed September 9, 2025, https://www.rr-research.no/ncs/docs/GhassemfinalExpEyeRes.pdf
12. Allogeneic Ex Vivo Expanded Corneal Epithelial Stem Cell Transplantation: A Randomized Controlled Clinical Trial - PubMed, accessed September 9, 2025, https://pubmed.ncbi.nlm.nih.gov/30688407/
13. Cell-based therapies for limbal stem cell deficiency: a literature review - Chen, accessed September 9, 2025, https://aes.amegroups.org/article/view/7277/html
14. Holoclar, INN-ex vivo expanded autologous human corneal ..., accessed September 9, 2025, https://www.ema.europa.eu/en/documents/product-information/holoclar-epar-product-information_en.pdf
15. Holoclar | European Medicines Agency (EMA), accessed September 9, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/holoclar
16. NICE recommends Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) for the treatment of moderate to severe limbal stem cell deficiency after eye burns - FirstWord Pharma, accessed September 9, 2025, https://firstwordpharma.com/story/4429422
17. Optimizing Vision Restoration: Experience with Holoclar Treatment, the Selection of a Qualified Treatment Center, Accessibility to Patients and Outcomes - Longdom Publishing, accessed September 9, 2025, https://www.longdom.org/open-access/optimizing-vision-restoration-experience-with-holoclar-treatment-the-selection-of-a-qualified-treatment-center-accessibility-to-pa-107069.html
18. EU/3/08/579 - orphan designation for corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns | European Medicines Agency (EMA), accessed September 9, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-579
19. Limbal Stem Cells Deficiency, Etiologies, Clinical Manifestations and Management - Pacific Eye Institute, accessed September 9, 2025, https://www.pacificeyemd.com/limbal-stem-cells-deficiency-etiologies-clinical-manifestations-and-management/
20. Holostem and Chiesi Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD), accessed September 9, 2025, https://www.holostem.com/2018/06/12/chiesi-and-holostem-announce-fda-orphan-drug-designation-for-gplscd01-for-treatment-of-limbal-stem-cell-deficiency-lscd/?lang=en
21. MULTINATIONAL, MULTICENTRE, PROSPECTIVE, LONG-TERM SAFETY AND EFFICACY FOLLOW-UP STUDY AFTER AUTOLOGOUS CULTIVATED LIMBAL STEM C - Onderzoek met mensen, accessed September 9, 2025, https://onderzoekmetmensen.nl/en/node/49307/pdf
22. Diagnosis and Management of Limbal Stem Cell Deficiency, accessed September 9, 2025, https://www.aao.org/eyenet/article/diagnosis-management-of-limbal-stem-cell-deficienc
23. Final appraisal determination Holoclar for treating limbal stem cell deficiency after eye burns - NICE, accessed September 9, 2025, https://www.nice.org.uk/guidance/ta467/documents/final-appraisal-determination-document
24. Treatment of limbal stem cell deficiency - EyeWorld, accessed September 9, 2025, https://www.eyeworld.org/2024/treatment-of-limbal-stem-cell-deficiency/
25. Holoclar®: first of its kind in more ways than one, accessed September 9, 2025, https://cdn.insights.bio/uploads/Attachments/Milazzo.pdf
26. Medicines containing the active ingredient ex vivo expanded autologous human corneal epithelial cells containing stem cells - (emc), accessed September 9, 2025, https://www.medicines.org.uk/emc/ingredient/3089
27. Holoclar, accessed September 9, 2025, https://ec.europa.eu/health/documents/community-register/2015/20150217130830/anx_130830_en.pdf
28. Italy leader in the regenerative medicine field with Holoclar - NCF International, accessed September 9, 2025, https://www.ncfinternational.it/italy-leader-in-the-regenerative-medicine-field-with-holoclar/
29. ex vivo expanded autologous human corneal epithelial cells containing stem cells (Holoclar®) - Scottish Medicines Consortium, accessed September 9, 2025, https://scottishmedicines.org.uk/media/5354/ex-vivo-holoclar-final-august-2020-updated-amended-180820-for-website.pdf
30. 316000 cells/cm2 living tissue equivalent ex vivo expanded autologous human corneal epithelial, accessed September 9, 2025, https://www.medicines.org.uk/emc/files/pil.12009.pdf
31. Holoclar, INN-ex vivo expanded autologous human corneal epithelial cells containing stem cells, accessed September 9, 2025, https://ec.europa.eu/health/documents/community-register/2024/20240222161610/anx_161610_en.pdf
32. EU Risk Management Plan (EU RMP) for Holoclar - European Medicines Agency, accessed September 9, 2025, https://www.ema.europa.eu/en/documents/rmp/holoclar-epar-risk-management-plan_en.pdf
33. Holocore - Health Research Authority, accessed September 9, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/holocore/
34. Europe approves Holoclar®, the first stem cell—based medicinal product - Chiesi Farmaceutici, accessed September 9, 2025, https://www.chiesi.com/en/europe-approves-holoclar%C2%AE-the-first-stem-cell%E2%80%94based-medicinal-product-
35. Holoclar is now available also in Czech Republic | Holostem S.r.l., accessed September 9, 2025, https://www.holostem.com/2021/05/12/holoclar-is-now-available-also-in-czech-republic/?lang=en
36. ex vivo (Holoclar) - Scottish Medicines Consortium, accessed September 9, 2025, https://scottishmedicines.org.uk/medicines-advice/ex-vivo-holoclar-full-smc2261/
37. On 22 February 2024, the European Medicines Agency ratified transition of Holoclar from conditional to full Marketing Authorisation - Holostem, accessed September 9, 2025, https://www.holostem.com/2024/04/05/european-medicines-agency-ratified-holoclar-full-marketing-authorisation/?lang=en
38. Search for holoclar - Clinical Trials register, accessed September 9, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=holoclar
39. Cell Therapy For LSCD - Review of Ophthalmology, accessed September 9, 2025, https://www.reviewofophthalmology.com/article/cell-therapy-for-lscd
40. From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5561870/
41. HOLOCORE-FU - NHS Health Research Authority, accessed September 9, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/holocore-fu/
42. Holoclar: ottenuta la ''full marketing authorization'' in EU e UK | Holostem S.r.l., accessed September 9, 2025, https://www.holostem.com/2024/04/05/holoclar-ottenuta-la-full-marketing-authorization-in-eu-e-uk/
43. Holosight - Health Research Authority, accessed September 9, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/holosight/
44. Holoclar 79,000 - 316,000 cells/cm2 living tissue equivalent - Summary of Product Characteristics (SmPC) - (emc) | 12009, accessed September 9, 2025, https://www.medicines.org.uk/emc/product/12009/smpc
45. Study Details | NCT02577861 | Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency | ClinicalTrials.gov, accessed September 9, 2025, https://clinicaltrials.gov/study/NCT02577861
46. Incentives, IP and smaller companies – the story of Chiesi and Holostem - Efpia, accessed September 9, 2025, https://www.efpia.eu/news-events/the-efpia-view/blog-articles/10112017-incentives-ip-and-smaller-companies-the-story-of-chiesi-and-holostem/
47. Holoclar - impianto (Cellule Epiteliali Corneali Umane Autologhe Espanse Ex Vivo E Contenenti Cellule Staminali) - Codifa, accessed September 9, 2025, https://www.codifa.it/farmaci/h/holoclar-cellule-epiteliali-corneali-umane-autologhe-espanse-ex-vivo-e-contenenti-cellule-staminali-oftalmici-trattamento-a-base-di-cellule-staminali
48. points Therapeutic use Clinical data - Haute Autorité de Santé, accessed September 9, 2025, https://www.has-sante.fr/jcms/c_2769517/en/holoclar-summary-ct15190
49. Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union - PubMed, accessed September 9, 2025, https://pubmed.ncbi.nlm.nih.gov/29280318/
50. First stem-cell therapy recommended for approval in EU - EATRIS, accessed September 9, 2025, https://eatris.eu/news/first-stem-cell-therapy-recommended-for-approval-in-eu/
51. Holostem Srl - medicina rigenerativa da cellule staminali epiteliali, accessed September 9, 2025, https://www.holostem.com/
52. Search Orphan Drug Designations and Approvals - FDA, accessed September 9, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=632218
53. Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD), accessed September 9, 2025, https://www.chiesi.com/en/chiesi-and-holostem-announce-fda-orphan-drug-designation-for-gplscd01-for-treatment-of-limbal-stem-cell-deficiency-lscd/
54. Holoclar Archivi | Holostem S.r.l., accessed September 9, 2025, https://www.holostem.com/tag/holoclar/
55. Centre for Regenerative Medicine: Holostem is now 10 years old, accessed September 9, 2025, https://www.magazine.unimore.it/site/home/notizie/articolo820044292.html
56. Graziella Pellegrini & Michele De Luca, winners of the 2020 Jeantet-Collen Prize - YouTube, accessed September 9, 2025, https://www.youtube.com/watch?v=kd26vFQ0mgw
57. Michele de Luca - EuroStemCell, accessed September 9, 2025, https://www.eurostemcell.org/michele-de-luca
58. Our company | Holostem S.r.l., accessed September 9, 2025, https://www.holostem.com/about-us/our-company/?lang=en
59. Interview with Michele De Luca – Epithelial cells and regrowing corneal epithelium, accessed September 9, 2025, https://www.eurostemcell.org/interview-michele-de-luca-epithelial-cells-and-regrowing-corneal-epithelium
60. Case Study: Holoclar | EuroGCT, accessed September 9, 2025, https://www.eurogct.org/case-study-holoclar
61. www.holostem.com, accessed September 9, 2025, https://www.holostem.com/about-us/our-company/?lang=en#:~:text=Holostem%20Terapie%20Avanzate%20was%20born,Farmaceutici%20S.p.A.%2C%20a%20leading%20Italian
62. Holostem Terapie Avanzate - 2025 Company Profile, Team & Competitors - Tracxn, accessed September 9, 2025, https://tracxn.com/d/companies/holostem-terapie-avanzate/__BAbahHt5oV4My-K4XAX3NQA6SK2I4J3mQVyUeuZMOOU
63. Holostem Terapie Avanzate Srl appoints Dr Marco Dieci as CEO, accessed September 9, 2025, https://www.holostem.com/2018/01/26/holostem-terapie-avanzate-srl-appoints-dr-marco-dieci-as-ceo/?lang=en
64. Limbal stem cell deficiency: Which procedure, when - Ophthalmology Times, accessed September 9, 2025, https://www.ophthalmologytimes.com/view/limbal-stem-cell-deficiency-which-procedure-when
65. A Review of the Diagnosis and Treatment of Limbal Stem Cell Deficiency - Frontiers, accessed September 9, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.836009/full
66. Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union - Oxford Academic, accessed September 9, 2025, https://academic.oup.com/stcltm/article/7/1/146/6454809
67. Stem cell therapy for cornea injuries demonstrates remarkable results in clinical trial, accessed September 9, 2025, https://www.news-medical.net/news/20250304/Stem-cell-therapy-for-cornea-injuries-demonstrates-remarkable-results-in-clinical-trial.aspx
68. Novel Stem Cell Therapy Repairs Irreversible Corneal Damage in Clinical Trial, accessed September 9, 2025, https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/calec-stem-cell-therapy-clinical-trial-repairs-corneal-damage
69. Stem Cell Therapy Restores Corneal Function - RegMedNet, accessed September 9, 2025, https://www.regmednet.com/stem-cell-therapy-restores-corneal-function/
70. Regeneration of Functional Human Corneal Epithelial Progenitor Cells – CIRM - CA.gov, accessed September 9, 2025, https://www.cirm.ca.gov/our-progress/awards/regeneration-functional-human-corneal-epithelial-progenitor-cells/
71. Early Clinical Outcomes of the First Commercialized Human Autologous Ex Vivo Cultivated Oral Mucosal Epithelial Cell Transplantation for Limbal Stem Cell Deficiency: Two Case Reports and Literature Review - MDPI, accessed September 9, 2025, https://www.mdpi.com/1422-0067/24/10/8926
72. Pre-Clinical Cell-Based Therapy for Limbal Stem Cell Deficiency - MDPI, accessed September 9, 2025, https://www.mdpi.com/2079-4983/6/3/863
73. Emerging approaches for ocular surface and corneal stromal regeneration: Recent advances and future perspectives - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12097421/
74. Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells and Limbal Epithelial Stem Cells for Ocular Surface Reconstruction - Oxford Academic, accessed September 9, 2025, https://academic.oup.com/stcltm/article/4/9/1052/6397335
75. Current Advances in Corneal Stromal Stem Cell Biology and Therapeutic Applications, accessed September 9, 2025, https://www.mdpi.com/2073-4409/13/2/163
76. Full article: Corneal Stromal Regeneration: Current Status and Future Therapeutic Potential, accessed September 9, 2025, https://www.tandfonline.com/doi/full/10.1080/02713683.2019.1663874